Skip to content
Homepage
Author:
Servier Pharmaceuticals LLC
Posted Date:
June 26, 2026
Servier Presentations at ISPNO 2026 Highlight Neuro-Oncology Leadership and Expanding Glioma Portfolio
Servier Pharmaceuticals LLC
June 26, 2026
Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.
Servier Pharmaceuticals LLC
June 25, 2026
Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
Servier Pharmaceuticals LLC
June 1, 2026
Promising Phase 1 Data for Servier’s Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026
Servier Pharmaceuticals LLC
June 1, 2026
Emiltatug Ledadotin (Emi-Le) Granted Breakthrough Therapy Designation by the U.S. FDA for Adenoid Cystic Carcinoma (ACC)
Servier Pharmaceuticals LLC
May 27, 2026
Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio
Servier Pharmaceuticals LLC
May 23, 2026
Day One and Servier Complete Enrollment in Pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a Front-Line Treatment for Pediatric Low-Grade Glioma (pLGG)
Servier Pharmaceuticals LLC
May 18, 2026
